Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.
The road to turning heart valve repair and replacement from a
surgical to an interventional procedure has been long and rocky,
but even among those who were once skeptical, there is little doubt
about where the path will lead. The operative questions now are not
if, but how long it will take to get there, and which of the many
companies now in this space will launch successful products.
Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device...
